title: Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib.
abstract: Imatinib is currently the standard treatment for chronic myeloid leukemia(CML). Previous studies have shown that imatinib affects bone metabolism in CML patients. However, these effects are not well-studied prospectively. The authors studied bone-mineral density (BMD) and bone metabolism in 17 CML patients and matched controls in 2007 and now repeated the analyses prospectively in 2011. All CML patients were in complete cytogenetic remission during this 4-year period and treated with 400 mg imatinib q.d. (n 5 15) or 600 mg imatinib q.d. (n 5 2). Mean treatment duration was 102 months (range 69–129) in 2011. The authors found that serum levels of parathyroid hormone increased significantly in the patients between 2007 and 2011, and seven out of 17 patients had secondary hyperparathyroidism in 2011. However, the mean areal and volumetric BMDs were stable in the CML patients over the 4-year-observation period. Moreover, the CML patients had significantly higher volumetric BMD in the cortical compartment when compared with controls in 2011 and 2007. Thus, despite a high incidence of secondary hyperparathyroidism,there were no signs of osteoporosis or osteomalacia in imatinib-treated CML patients as suggested earlier.
authors.affiliation: Section of Hematology, Institute of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden. sofia.jonsson@vgregion.se.
authors.forename: Sofia
authors.initials: S
authors.lastname: Jönsson
authors.forename: Therese
authors.initials: T
authors.lastname: Standal
authors.forename: Bob
authors.initials: B
authors.lastname: Olsson
authors.forename: Dan
authors.initials: D
authors.lastname: Mellström
authors.forename: Hans
authors.initials: H
authors.lastname: Wadenvik
mesh_terms: D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D015415:Biomarkers; D015519:Bone Density; D002118:Calcium / Q000097:blood; D024042:Collagen Type I / Q000097:blood; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000139:chemically induced*; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008274:Magnesium / Q000097:blood; D008297:Male; D008593:Menopause; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood; D010455:Peptides / Q000097:blood; D010879:Piperazines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D012907:Smoking / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D015415:Biomarkers; D024042:Collagen Type I; D010281:Parathyroid Hormone; D010455:Peptides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D000068877:Imatinib Mesylate; D000469:Alkaline Phosphatase; D008274:Magnesium; D002118:Calcium